Baron, F., Suciu, S., Amadori, S., Muus, P., Zwierzina, H., Denzlinger, C., . . . de Witte, T. (2012). Value of infliximab (Remicade(®)) in patients with low-risk myelodysplastic syndrome: Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Ferrata Storti Foundation.
Chicago ZitierstilBaron, Frédéric, et al. Value of Infliximab (Remicade(®)) in Patients With Low-risk Myelodysplastic Syndrome: Final Results of a Randomized Phase II Trial (EORTC Trial 06023) of the EORTC Leukemia Group. Ferrata Storti Foundation, 2012.
MLA ZitierstilBaron, Frédéric, et al. Value of Infliximab (Remicade(®)) in Patients With Low-risk Myelodysplastic Syndrome: Final Results of a Randomized Phase II Trial (EORTC Trial 06023) of the EORTC Leukemia Group. Ferrata Storti Foundation, 2012.